Appointments: Sanofi, Recipharm, Axovant, e-Therapeutics & Diplomat

This week’s roundup includes the appointment of Sanofi Genzyme’s executive vice president and various high-level appointments by companies including Recipharm, e-Therapeutics, Diplomat Pharmacy and Axovant.

Sanofi has appointed Bill Sibold executive vice president of Sanofi Genzyme and member of the executive committee – effective July 1, 2017. Sibold succeeds David Meeker, who will leave the company at the end of June after 23 years of working at Genzyme and Sanofi. Sibold joined Sanofi in 2011 as head of the MS franchise and currently is head of Sanofi Genzyme’s global multiple sclerosis, oncology and immunology organization.

Meeker will be joining Rhythm’s board of directors as chair. Rhythm is a biopharma company developing peptide therapeutics for rare...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Executives On The Move

Scrip-Leadership (Free-2): Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 
• By 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By 

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

 

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

Executives On The Move: A New CEOs for ACADIA Pharmaceuticals And G1 Therapeutics Among This Week's Changes

 
• By 

​​​<p>Executive Summary​​ </p> ​​<br> <p>Other recent moves in the industry include changes at the top at Adocia, CSL and Entrada Therapeutics.</p>

More from Leadership

An Activist Investor Makes A Play For Pfizer

 

Starboard Value has reportedly bought a $1bn stake in Pfizer with an ambition to turn the big pharma around. But growth, not cost cuts, are Pfizer’s challenge.

Executives On The Move: A New CEOs for ACADIA Pharmaceuticals And G1 Therapeutics Among This Week's Changes

 
• By 

​​​<p>Executive Summary​​ </p> ​​<br> <p>Other recent moves in the industry include changes at the top at Adocia, CSL and Entrada Therapeutics.</p>

Executives On The Move: A New CEOs for ACADIA Pharmaceuticals And G1 Therapeutics Among This Week's Changes

 
• By 

​​​<p>Executive Summary​​ </p> ​​<br> <p>Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements</p>